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Abstract
A new strategy for the rapid identification of new malaria antigens based on protein structural
motifs was previously described. We identified and evaluated the malaria vaccine potential of
fragments of several malaria antigens containing α-helical coiled coil protein motifs. By taking
advantage of the relatively short size of these structural fragments, we constructed different poly-
epitopes in which 3 or 4 of these segments were joined together via a non-immunogenic linker.
Only peptides that are targets of human antibodies with anti-parasite in vitro biological activities
were incorporated. One of the constructs, P181, was well recognized by sera and peripheral blood
mononuclear cells (PBMC) of adults living in malaria-endemic areas. Affinity purified antigen-
specific human antibodies and sera from P181-immunized mice recognised native proteins on
malaria-infected erythrocytes in both immunofluorescence and western blot assays. In addition,
specific antibodies inhibited parasite development in an antibody dependent cellular inhibition
(ADCI) assay. Naturally induced antigen-specific human antibodies were at high titers and
associated with clinical protection from malaria in longitudinal follow-up studies in Senegal.
Introduction
It is estimated that there are up to 500 million cases of malaria every year and that about one
million children living in sub-Saharan Africa die within the same period.1 Over the past few
years, appreciable progress has been made in the control of malaria infection in some parts
of sub-Saharan Africa.2 Further reduction in morbidity and mortality as well as possible
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eradication of the disease will depend to a large extent on safe and effective vaccines.
However there is currently no vaccine against malaria and only handful vaccine candidates
are currently being evaluated.
The publication of the full genome of Plasmodium falciparum3 opened new opportunities
for the development of novel drugs and vaccines against malaria. The aim of our group is to
explore these vastly untapped data and discover new malaria antigens by combining
bioinformatics and chemical peptide synthesis by using in vivo/in vitro parameters that are
associated with protection against malaria. In our previous work4 we described the
identification and production of 95 segments derived from 70 P. falciparum-3D7
erythrocytic stage proteins predicted to have α-helical coiled coil protein motifs. These α-
helical coiled coil protein motifs consist of heptad repeats (abcdefg)n with hydrophobic
residues at a and d positions while the other residues are generally hydrophilic. The
synthesized fragments readily assume their native oligomeric structure.5
Out of the 95 segments synthesized, 12 polypeptides were found to be targets of in vivo
parasite growth inhibition in an ADCI assay. In order to maximize the proportion of the
general host population that will respond to such a candidate vaccine while conserving the
individual functional capacities of the constituent polypeptides (with additional likelihood of
synergism), we then synthesized constructs consisting of 2-4 polypeptides joined together by
the non-immunogenic a modified diethylene glycol linker (DEG). Selection of the
constituent polypeptides was based on the length of each fragment, sequence conservation,
antigenic recognition by semi-immune adult sera, immunogenicity in mice and biological
activities of affinity purified specific human antibodies in ADCI assays.
Of the different poly-epitopes we constructed, we report here the results for P181, which is
composed of the 3 fragments, P90, P77 and P27 that are derived from the proteins
PFD0520c (25 kD), PF08_0048 (247 kD), PFF0165c (160 kD), respectively [Plasmodb.org;
manuscript submitted]. These peptides had been identified as the most promising candidates
in our previous analysis.4
Materials and Methods
Peptide synthesis and antigen characterization
The polypeptides were synthesized using solid-phase Fmoc chemistry6 with Applied
Biosystem synthesizer 431A and 433A (Foster City, 179 CA). Derivatized diethylene glycol
(DEG, Merck Chemicals Ltd, Nottingham, UK) was inserted in between the synthesis of the
three fragments P90, P77 and P27
(TKKLNKELSEGNKELEKLEKNIKELEETNNTLENDIKV-DEG-
EKLKKYNNEISSLKKELDILNEKMGKCT-DEG-
KKRNVEEELHSLRKNYNIINEEIEEIT). The resulting construct was HPLC purified and
the purity (>90%) was confirmed by analytic C18 HPLC and mass spectrometry (MALDI-
TOF; Applied Biosystem) All reagents used were purchased from Fluka (Buchs,
Switzerland) and Novabiochem (Laufelfingen, Switzerland). A custom-made synthesis was
performed by Almac Sciences, Craigavon, Northern Ireland. Purity was >95% as judged by
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analytical HPLC and mass spectrometry analysis shows material with the predicted MW of
11945.9 (data not shown).
The circular dichroism spectrum of the constructs was assessed with a JASCO J-810
spectrometer (JASCO Corporation, Japan). The measurements were with 0.2 mg/ml of the
construct dissolved in water at 22°C and at pH 7.3.
Analytical ultracentrifugation was carried out in ProteomeLab XL-I analytical
ultracentrifuges (Beckman Coulter, Palo Alto, CA). Sedimentation velocity experiments
followed the standard protocol.7-9 In brief, peptide P181 samples at final concentrations of
0.1, 0.2, 0.4, and 0.8 mg/ml were dialyzed into a buffer composed of 14 mM NaCl, 0.3 mM
KCl, 0.4 mM sodium phosphate, 0.2 mM potassium phosphate, pH 7.4 and sedimented at
59,000 rpm at 10°C. Interference optical fringe shift profiles were fitted with the c(s)
model.10 For the partial-specific volume, a value of 0.739 ml/g was predicted for the
temperature-corrected partial specific volume from the amino acid composition and the
tabulated data from Cohn & Edsall11 and the density of PEG.12 The density and viscosity of
the buffer were measured using a DMA5000 densimeter and an AMVn automated micro
viscometer (both from Anton Paar, Graz, Austria), respectively. The prediction of
hydrodynamic parameters from model structures was based on the program BEST [please
insert new reference to the following paper http://www.ncbi.nlm.nih.gov/pubmed/
15116362].
Sedimentation equilibrium experiments were conducted following the standard protocol.7 In
brief, 180 microliter samples at concentrations of 0.1, 0.3, and 1.0 mg/ml were sedimented
to attain equilibrium at 25,000 rpm and 34,000 rpm at 10°C. Absorbance optical scans were
acquired at 280 nm. The global analysis of all data sets was performed with the software
SEDPHAT10,13 using the principle of soft mass conservation,14 and a model for monomer-
dimer self-association in chemical and sedimentation equilibrium following mass action law,
accounting for a non-participating species. Error estimates were obtained from Monte-Carlo
analysis using 1000 iterations and a confidence level of one standard deviation.
Human sera
Anonymized archived human serum samples from malaria endemic areas and from
Switzerland were used. The sera samples were collected from malaria-endemic regions of
Burkina Faso, Tanzania, Papua New Guinea and Senegal and were the same samples used in
our previous study.4,15 Briefly, the samples from Burkina Faso were collected from donors
living in the village of Goundry in the province of Oubritenga. Ethical approval was
obtained from the Ministry of Health, Burkina Faso. The Tanzanian samples were obtained
from donors in Kikwawila village in Morogoro region. Ethical approval was obtained from
the Tanzanian Commission for Science and Technology. Additional sera samples obtained
from Papua New Guinea were collected in the Maprik District of the East Sepik Province,
during a cross sectional survey in July 1992 within the framework of the Malaria Vaccine
Epidemiology and Evaluation Project (MVEEP) supported by the United States Agency for
International Development. The area is highly endemic for malaria. Ethical clearance for
MVEEP was obtained from the Papua New Guinea Medical Research Advisory Committee.
Blood samples were obtained by venipuncture into tubes containing EDTA. The study
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design in Senegal received clearance from the national Senegalese ethical committee.
Negative control samples were Swiss adult donors with no history of malaria and no
previous travel to malaria-endemic areas.
Human PBMCs
PBMC were obtained from adult donors living in Lagos, South-West Nigeria where malaria
transmission is high all year round with seasonal peaks during the rainy season. Ethical
approval was obtained from Lagos State University Teaching Hospital (LASUTH) ethical
review committee.
Antigen recognition by human sera
The recognition of P181 and each of its constituent polypeptide was assessed by ELISA
with sera of adults living in malaria endemic regions of Burkina Faso, Tanzania, Papua New
Guinea and Senegal. Each well in a 96-well microtiter plate (Maxisorb F96, Nunc, Roskilde,
Denmark) was coated with 50 μl of each antigen (concentration 1 or 5 μg/ml for P181 and
single fragments, respectively) and incubated overnight in humid chamber at 4°C. Wells
were washed 4 times with PBS-0.05% Tween-20 and blocked for 1 h with 200 μl per well of
5% milk PBS-0.05% Tween-20. Sera of adults living in Burkina Faso (n=37) and Tanzania
(n=42) were added at 1:200 diluted in 2.5% milk PBS-0.05% Tween-20. This was incubated
for 1 h at room temperature. The plates were then washed and 50 μl/well of alkaline
phosphatase-conjugated goat anti-human polyvalent immunoglobulin (Sigma, MO, USA)
was added at 1:1000 dilutions. Wells were washed before 50 μl of nitrophenylphosphate
solution (Sigma, MO, USA) was added. OD was measured at 405 nm. The negative controls
(n=8) were sera of adult Europeans with no previous history of malaria or travel to malaria-
endemic region. Test samples were considered positive when the measured OD was higher
than that of the sum of average OD and 3SD of the negative controls.
T-cell proliferation
Frozen PBMCs collected from adult donors living in Nigeria were thawed and counted. Five
replicates containing 2×105 cells/well were cultured with 10 μM of each of the constituent
polypeptide and 5 μM of P181, respectively. The complete culture medium used consisted
of RPMI (Sigma) supplemented with glutamine, 100 IU/ml Penicillin-Streptomycin, 100 μM
non-essential amino acids, Kanamycin (Invitrogen, Paisley, UK), 2 mM sodium pyruvate
(Invitrogen) and 8% human AB serum (Blutspendendienst SRK, Bern, Switzerland). The
positive control was a mixture of tetanus toxoid (Pasteur Merieux, Lyon, France),
Mycobacterium tuberculosis purified protein derivatives (PPD) (SSI, Copenhagen,
Denmark) and Candida (NIBSC, London, UK).
On day 5, 1 μCi of thymidine diluted in the culture medium was added. The cultures were
harvested 24 hours later, and radioactivity was measured as count/min. The stimulation
index (SI) was calculated as (average count/min)/(count/min in culture without antigens). SI
>2 was considered significant.
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Immunogenicity in mice
Two syngeneic and one outbred strains of mice, C3H, CBF1 and ICR respectively (mice, 4
mice/group) were injected with 20 μg of the poly-epitope P181 or with each of the
constituent polypeptides (P90, P77 and P27) formulated in Montanide ISA 720 (35 μg/
mouse). Immunogenicity of P181 formulated with Alhydrogel (1 mg/mouse) and GLA-SE
(20 μg/mouse), an oil-in water stable emulsion containing a lipid A-like synthetic
compound16-17 was also assessed in C3H, CBF1 and ICR mice. Each mouse was injected
either subcutaneously at the base of the tail (Montanide and GLA-SE, 50 μl/mouse) or
intraperitoneally (Alum, 500 μl/mouse) at 0, 3 and 8 weeks. The induced antibody responses
were assessed by ELISA 10 days following second and third immunizations. Antibody titers
were assessed by 1:3 serial dilutions of the sera starting from 1:100. The ELISA protocol
used was same as that described above for human antibodies with the exception for mouse
polyvalent immunoglobulin (Sigma, MO, USA) as second antibody. The end point is taken
as the last dilution with OD value greater than average OD of control sera + 3SD.
Affinity purified human antibodies
Human antibodies specific for the poly-epitope P181 and the constituent polypeptides were
purified from pooled sera (50 ml) of adults living in Papua New Guinea. The pooled serum
was centrifuged at 3,000 rpm for 5 min and the supernatant was filtered and further diluted
at 1:5 in PBS/0.5 M NaCl. Two to five mg of each polypeptide was coupled with CNBr-
activated Sepharose 4B (Amersham Biosciences, Büdendorf, Switzerland). The serum
solution was then mixed with the antigen-coupled beads and stirred on wheel overnight at
4°C. The solution was then centrifuged at 3,000 rpm for 20 min and the beads were washed
twice first with 5 ml of 20 mM Tris/0.5 M NaCl and then with 20 mM Tris. The specific
antibodies were eluted with 0.1M glycine pH 2.5 at room temperature. Three fractions were
collected in 100 μl of neutralization solution (10 PBS, pH 7.4). Antibodies were filtered
through a 0.22 μm syringe filter, aliquoted and stored at -80°C. The antibody concentration
was determined by the absorbance of each fraction at 280 nm.
Immunofluorescence assay (IFA)
For indirect immunofluorescence microscopy, infected RBCs were smeared onto glass slides
and fixed in ice-cold acetone:methanol (1:1, vol/vol) for 10 min. Slides were blocked for 1h
in 3%BSA/PBS and probed with one of the following primary and secondary antibodies:
mouse anti-P27 (1:200), mouse anti-P90 (1:200) mouse anti-P77 (1:200), human affinity
purified sera specific to P27 (1:2000) P90 (1:1000) and P77 (1:500), Cy3-labelled anti-
mouse IgG (1:500), Cy3-labelled anti-human IgG (1:500; Jackson ImmunoResearch,
Suffolk, UK) and Alexa 488-conjugated anti-rabbit IgG (1:200; Invitrogen). The slides were
mounted in vectashield (Vector Laboratories, Burlingame, CA, USA) supplemented with
DAPI for nucleus staining. Fluorescence microscopy was performed on a Leica fluorecence
microscope DM-5000B using the × 60 oil immersion lens and documented with Leica
DC200 digital camera system.
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Western Blot analysis
Protein extracts were separated on a 10% SDS-polyacrylamide gel and transferred to
nitrocellulose (0.2 mm, Whatman Schleicher + Schuell, Florham Park, NJ) under cooling
conditions for 1 h at 80V and an additional hour at 100V. The membrane was blocked for 1
h in PBS/3% milk powder at room temperature and the primary antibody was diluted 1:500
in PBS and 1.5% milk powder. The membrane was incubated in the primary antibody
solution overnight at 4°C, washed 8× in PBS, 0.05% Tween 20 and incubated with a
peroxidase-conjugated goat anti-mouse IgG antibody (1:3000, Sigma). Bound secondary
antibodies were visualized using Western Lightning® (PerkinElmer Life Sciences,
Schwerzenbach, Switzerland).
Antibody dependent cellular inhibition (ADCI) assay
The inhibition of P. falciparum (3D7 strain) growth in vitro in the presence of human
monocytes (MN) and antigen-specific antibodies was carried out by methods described
elsewhere.18-19 Mature schizonts from a synchronized parasite culture were diluted at
starting parasitemia of 0.5 % in normal human AB+ type RBCs and the hematocrit was
adjusted to 2.5% with RPMI 1640 culture medium. Duplicate assays were set up in
preheated 96-wells flat bottom sterile plastic plates (TPP, Trasadingen, Switzerland)
containing 2×103 MN/well and by addition of 50 μl of parasite culture mixed with 50 μl of
RPMI and various dilutions of each pool of sera at final concentration of 0.5%-10%. Control
wells with parasite culture and RPMI were done in parallel. The plates were incubated in a
candle jar at 37°C, in a 5% CO2 incubator for 96 h. Thin blood smears for each well were
fixed in methanol and stained in eosin and methylene blue. The parasitemia was determined
by microscopic examination and counting of at least 5,000 RBCs in duplicate. The Specific
Growth Inhibitory index (SGI) which estimates the parasite growth inhibition due to the
effect of test Abs cooperating with MN was calculated as follows: SGI = 100 × (1 - (%
parasitemia with MN and test Abs/% parasitemia test Abs)/(% parasitemia with MN and N-
IgG/% parasitemia N-IgG)).
For each Ab tested, duplicate wells included the following controls: 1) non-specific
monocytic inhibition, both MN + parasite, and MN + normal (N)-IgG + parasites and 2)
direct inhibition by control or test IgG, both N-IgG + parasites, and test Abs + parasites.
Pooled immunoglobulins of Africans (PIAG) and N-IgG were used at a final concentration
of 1 mg/ml and as positive and negative controls, respectively. Immunopurified test human
Abs were used at 15μg/ml while mouse sera were used at different dilutions.
Human antibody response and association with protection
The inhabitants of Ndiop village, in Senegal (with 300-350 villagers), where malaria
transmission is seasonal, were involved in a prospective study using a stringent protocol of
clinical follow-up including the daily active surveillance of each villager by a medical staff
present seven days a week and 24 hours a day. The presence of each individual was checked
on a daily basis and each febrile episode was recorded. A malaria attack was defined as an
episode of fever with temperature ≥38.5°C associated with a parasite density exceeding a
parasite threshold of 3000 parasites/μl. Therefore both the occurence of clinically defined
malaria attacks and the actual time spent in Ndiop by each villager were available and
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included in statistical analyses. The informed consent of each villager enlisted in this
protocol (or that of the parents in the case of children) was obtained at the beginning of the
study and was renewed at the beginning of each year of the survey. The study design
received clearance from the national Senegalese ethical committee.20
Antibody responses determined in Ndiop village were tested by multivariate analysis using
stepwise regression process available in the JMP® (SAS) software. The number of malaria
attacks identified during the 3 years of active follow-up following the plasma sampling was
used as a Log10+1-transformed continuous variable. Both age and Log10-transformed
antibody responses were simultaneously tested as explanatory variables and controlled for to
explain the number of malaria attacks identified for each individual. The F ratios, (i.e., the
ratio of the mean square for the effect divided by the mean square of the error) were
calculated as well as probabilities associated with F ratio values (i.e., the probability was
tested that, given that the null hypothesis was true, an even larger F statistic would occur due
to random error).21
Results
Synthetic polypeptides consisting of 2-4 fragments with α-helical coiled coil protein motif
described in our previous publication4 were co-linearly synthesized by using a non-
immunogenic linker, di-ethylene glycol (DEG). The P181 construct is composed of P90 (38
amino acids), P77 (28 amino acids) and P27 (27 amino acids) fragments with a modified
diethylene glycol inserted between the fragments (see Materials and Methods). The selection
of these 3 among 12 candidates that were previously identified,4 was guided by the
frequency of recognition by human antibodies, their in vitro biological activities,
immunogenicity in mice and fragment length to obtain a poly-epitope amenable to peptide
synthesis.22 The linking of the 3 epitopes stabilizes the α–helical conformation of the single
epitopes as seen in Fig. 1. In fact, the CD profile of P181 with minima at 207 and 222 nm
and a high intensity band at 207 nm indicates a high content of α-helical structures in
contrast to those of the single epitopes.
The sedimentation coefficient distribution c(s) exhibited distinct peaks of approximately
equal areas at s20,w values of ∼1.2 S and ∼1.8 S, with a best-fit average frictional ratio of
∼1.41 corresponding to species of ∼ 10 kDa and 18 kDa. Within the typical error of this
analysis, this strongly suggests the presence of monomers and dimers. The measured
frictional ratio is best consistent with hydrodynamic properties of the moderately compact
structures in Figure 2, 1 and 2, rather than the most extended form 3.
In order to examine the association state in more detail, we next performed sedimentation
equilibrium experiments with samples at several loading concentrations. Cell-average
molecular weights were in between that of the monomer and dimer. The global analysis with
a monomer-dimer self-association model resulted in an estimated equilibrium constant of
KD = 115 (±15) μM.
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Antigenic recognition
Sera—The majority of the adult donor population living in Burkina Faso. Tanzania and
PNG recognized the constituent fragments (range 52-83%, Table 1). The prevalence of
recognition of the poly-epitope was similar or higher than the individual components (73%,
79% and 90% respectively for BF, TZ and PNG samples). As expected, average ELISA OD
values for P181 were higher than those observed for the individual epitopes.
T-cell proliferation—Peripheral blood mononuclear cells of adults living in malaria-
endemic region of South-West Nigeria (12 out of 13) proliferated when incubated with P181
solution. This proportion was relatively higher than that of the single constituents (range
23-54%). In addition, the average SI obtained with P181 (9.8) was also higher as compared
to that obtained with each peptide (2.2-3.2; Table 2).
Human antibodies specific for P181
Human antibodies specific for P181 and each of its constituents were obtained from pools of
sera obtained from adults living in Papua New Guinea. The reactivity and specificity of
purified antibodies were confirmed by ELISA (Table 3). Antibodies specific for each of the
components recognized the P181. Likewise, anti-P181 antibodies recognized each of the
individual fragments.
The P181-specific mouse or human antibodies recognized parasite structures on P.
falciparum-infected erythrocytes in IFA (Fig. 3a). They also produced distinct bands by
western blotting of infected erythrocyte lysates (Fig. 4a).
Immunogenicity in mice
High antibody titers were induced in inbred and outbred mice immunized with P181
formulated with Alhydrogel, GLA-SE and Montanide AS 720 in several strains of mice. The
induced antibodies also recognized all or part of the individual constituents depending on the
adjuvant or mouse strain used (Table 4a and b). Similarly, anti-sera specific for P27, P77
and P90 recognize the poly-epitope.
All mouse sera recognized parasite structures in malaria-infected erythrocytes by IFA (Fig.
3b) and in lysates in Western blots (Fig. 4b). PF08_0048 has a predicted size of 247 KDa,
thus the full length protein was not detected on Western Blots.
ADCI and association with protection
For ADCI experiments, only those experiments in which an optimal growth rate of the
parasite was obtained (e.g. >6-fold increase per 48 h), were kept for analysis. Table 5 shows
the SGI values obtained as compared to the positive control, the pool of Ivory Coast adult
immunoglobulins previously employed in passive transfer experiments in humans. As the
ADCI assay is not a quantitative assay and because there is a dose dependent increase in
ADCI activity only at very low antibody concentrations [19], whereas, at higher
concentration, there is a plateau of activity, all tested antibodies were assessed at a single
antibody concentration of 15 μg/ml.
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To assess the association with protection longitudinal follow-up studies were performed
among inhabitants of Dielmo, Senegal. The first study involved 45 individuals among whom
22 had no malaria attack during a 3-year follow-up period and 23 had one or more malaria
attacks during the same period. Both have the same age-distribution. These results were also
confirmed among 102 Ndiop inhabitants while also adjusting for age and occurrence of
malaria attacks.
In multivariate analysis, when both age and the time spent in the village were systematically
controlled in each statistical test, antibodies to P27 were high when the number of malaria
attacks was low after 1 and 3 years of active and daily clinical follow-up of the villagers
(after 1-year F ratio = 8.92 and p = 0.0047, after 3 years F ratio = 11.74; p = 0.0012; Table
6). For P181, after 1 year of follow-up, the F ratio was 11.43; p = 0.0016 whereas after 3
years of study, the F ratio was 15.48; p = 0.0003). For a given age and a determined period
of presence in the village, a two-fold increase in anti-P27 antibody response was potentially
associated with a 1.5-fold decrease in the number of malaria attacks expected to occur after
3 years of follow-up. The mean age of the cohort studied was 16.1 ± 11.1 years. The mean
period of time spent in the village was 319 ± 85 days during the first year of follow-up (i.e.
people remained continuously in the village during 87.4% of the year) and 862 ± 282 days
during the 3 years of follow-up (people remained permanently in the village during 78.6% of
the 3 year period). A two-fold increase in anti-P181 antibody responses was potentially
linked with a 1.6 fold reduction in the number of malaria attacks expected during the same
period of study. The marked association between protection and anti-P181 responses reflects
the contribution of the results obtained when testing anti-P27 antibody responses; the
representation of P27 epitopes within the multi-epitope construct also suggests that anti-P27
constitute a substantial part of Abs to P181.
Discussion
As a follow-up to our previous studies4,23 in which several novel B cell epitopes were
identified as possible targets of a protective immune response against P. falciparum, we
describe here the evaluation of a poly-epitope constructed by selecting 3 promising
fragments, P90, P77 and P27 derived from 3 novel proteins PFD0520c, PF08_0048,
PFF0165c. By combining fragments with specific immunological properties (e.g high
antigenicity, high immunogenicity, association with protection in humans, high activity of
specific antibodies in ADCI assay), we attempted to integrate these features in a single
construct and, thus, increase the capacity of the poly-subunit antigen to induce effective
immune responses in a genetically heterogeneous human populations since each fragment
can act as a helper T-cell epitope. Use of hybrid recombinant constructs as vaccine
candidates has already been applied for malaria, influenza, HIV, tuberculosis and
allergy.24-28
With regard to the structural characteristics of P181, the data obtained by CD and analytical
ultracentrifugation measurements indicate that the poly-epitope has a high content of α-
helical structure, and is a dimer in equilibrium with its monomer, thus, suggesting a two-
strand α-helical coiled coil conformation (Fig. 2). Indeed, recombinant protein PFD0520c,
from which P90 is derived, has also been determined to be a dimer with high α-helical
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structure content (manuscript in preparation), and P27 is predicted to fold as a dimer. The
linking together of several epitopes stabilises the α-helical structure of individual
components as indicated by the CD data. Changing the order of peptides in the poly-epitope
does not seem to substantially change the physico-chemical and immunological properties of
the new construct (data not shown).
The resemblance of the poly-epitope structure to that assumed by the individual fragments
within the corresponding proteins has been the basis of our initial epitope selection, and is of
paramount importance to the identification and development of an erythrocytic malaria
vaccine where protection is mediated by antibodies.
With regards to the antigenic properties of P181, the poly-peptide was better recognized by
antibodies (similar or higher prevalence and higher average OD) and by PBMC from
Nigerian donors in terms of prevalence and SI. Similarly, when considering immunogenicity
in mice, the poly-epitope was generally more immunogenic in terms of antibody titers than
the individual fragments. In addition, it provided T-cell help to those individual antigens,
which were not immunogenic by themselves in certain strains (see P90, for example; table
4a). This concept is important when considering the use of P181 as vaccine candidate in
humans with respect to a mixture of single components.
Affinity-purified human antibodies and mouse sera specific for P181 and its components
recognized parasitic structures in IFA and highlighted a limited number of proteins at MW
consistent with the size of the corresponding parasitic proteins (24, 240 and 160 kD) or their
fragments, except for anti-P90 antibodies which consistently failed to bind proteins of the 25
kD range (manuscript in preparation). Human specific antibodies to the 4 constructs are all
active in ADCI, consistent with our previous observation for the constituent polypeptides.4
Of note however is the fact that the observed ADCI activity of P181 is lower than that
observed for P27, but higher than that seen for P77 and P90. Thus, it reflects the mean
ADCI activity of the individual components. Alternatively, this might reflect experimental
variation in the ADCI assay, which is only a semi-quantitative assay, or a competition of
different antibodies with FcγRII and FcγRIII receptors present on human monocytes.17
More work is needed to clarify this point. Finally, the association of the antibody response to
protection from malaria indicate a stronger relationship with P181 than for its single
components. We would like to think that this is due to the better structural similarity of the
poly-epitope to the native structure of the individual components.
In summary, given the higher prevalence and recognition of P181 by natural antibodies in
ELISA, its higher stimulation index in the T-cell proliferation assay, its greater
immunogenicity in mice, together with the inhibitory activity of antibodies specific to P181
as assessed by ADCI and with the strong association with protection from clinical malaria as
determined in a 3-year longitudinal study in adults, P181 appears to be a stronger vaccine
candidate than the individual peptides and warrants a further development as a malaria
vaccine.
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Finally, since chemical synthesis of larger fragments are now possible,21 it is conceivable to
design constructs similar to P181 but with a wider immunological spectrum by including P.
falciparum and P. vivax fragments.
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Fig. 1. CD profile of P181 and its constituents
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Fig.2. Structural model of P181
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Fig. 3.
(a) Immunofluorescence staining of P. falciparum infected erythrocytes with affinity
purified human antibodies (P27, P77, P90 and P181 in red). First row: P27 specific human
antibodies indicate localization of the corresponding protein PFF0165c to the periphery of
the RBC (in red). Nucleus stained with Hoechst (in blue), transmission light microscopy of
the infected red blood cell (differential interference contrast, DIC) and merged picture of the
nucleus and P27 specific antibody signal (merge).Second and third rows: P77 or P90
specific human sera indicate the localization of the corresponding proteins PF08_0048 or
PFD0520c respectively to the cytoplasma of the parasite. Nucleus stained with Hoechst (in
blue), transmission light microscopy of the infected red blood cell (DIC) and merged picture
of the nucleus and P77 or P90 signal (merge). Fourth row: P181 specific human antibodies.
Signal at the periphery of the RBC and the cytoplasm of the parasite indicates that sera
raised against the poly-epitope recognizes the three corresponding proteins PFF0165c,
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PF08_0048 and PFD0520c. Nucleus stained with DAPI (in blue), transmission light
microscopy of the infected red blood cell (DIC) and merged picture of the nucleus and P181
(merge).
(b) Immunofluorescence staining of P. falciparum infected erythrocytes with murine
antibodies against P27, P77, P90 or P181,respectively. First row: P27 specific human
antibodies indicate localization of the corresponding protein PFF0165c to the periphery of
the RBC (in red). Nucleus stained with Hoechst (in blue), transmission light microscopy of
the infected red blood cell (DIC) and merged picture of the nucleus and P27 specific serum
signal (merge). Second and third rows: Localization of PF08_0048 and PFD0520c using
mouse sera raised against P77 and P90 respectively (in red). Staining indicates localization
of both proteins to the parasite cytoplasm. Nucleus stained with DAPI (in blue),
transmission light microscopy of the infected red blood cell (DIC) and merged picture of the
nucleus and P77 or P90 respectively. Fourth row: Signal in the infected RBC using mouse
sera raised against the poly-epitope P181 (in red). Signal at the periphery of the RBC and
the cytoplasm of the parasite indicates that sera raised against the poly-epitope recognizes
the three corresponding proteins PFF0165c, PF08_0048 and PFD0520c. Nucleus stained
with DAPI (in blue), transmission light microscopy of the infected red blood cell (DIC) and
merged picture of the nucleus and P181 (merge).
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Fig 4.
(a) Immunoblot from saponin-lysed 3D7 late stage parasite extracts electrophoresed under
reducing conditions. Immunoblot was probed with affinity purified human α-P181, α-P27,
α-P77, α-P90, normal human serum (NHS) and affinity purified human α-MSP-2-3D7
which was used as a positive control. Relative size standards are indicated on the left in kDa.
(b) Immunoblot from saponin-lysed 3D7 late stage parasite extracts electrophoresed under
reducing conditions. Immunoblot was probed with mouse α-P181, α-P27, α-P77, α-P90,
normal mouse serum (NMS) and α-R634 which was used as a positive control. α-R634 was
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a second bleed sera obtained from rabbits immunized with recombinant MSP-2. Relative
size standards are indicated on the left in kDa.
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Table 2
Human PBMC proliferation in the presence of different antigens
Prev - (%) SI
P181 92 9.8
P90 23 3.2
P77 54 3.1
P27 38 2.2
PBMC proliferation of adult donors living in Nigeria (N=13). Each antigen was put in culture in 200 μl at 10 μM (5 μM for P181) together with
2×105 PBMC at 37°C for 5 days. The cultures were then pulsed overnight with 3H-thymidine, and stimulation index (SI) was regarded significant
when the radioactivity of stimulated over unstimulated cultures was ≥ 2.
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Table 3
Cross reactivity of human antigen-specific antibodies
IgG anti-
P181 P90 P77 P27
P181 ++++ ++ + +++
P90 + +++ - -
P77 + - ++ -
P27 ++ - - +++
Affinity purified antibodies specific for P181 and its constituents recognize P181 and its constituents and vice-versa (+ to ++++ represent positive
ELISA at dilutions 1:300 to 1:8100).
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Table 5
In vitro inhibition of P. falciparum 3D7 strain by human affinity purified antibodies
specific for P181 and its constituent peptides
SGI*
P181 55%
P90 43%
P77 36%
P27 106%
*SGI- specific growth inhibition of human specific antibodies.
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Table 6
The antibody responses found in Ndiop were tested in multivariate analysis by stepwise regression. The
number of malaria attacks identified during the 3 years following the serum sampling was used as a
continuous variable. Both age and Log10-transformed antibody responses were simultaneously tested as
explanatory variables.
Anti-peptide IgGs: F ratios: p values:
IgG1-P27 11.74 0.001
IgG3-P77 3.31 0.076
IgG1-P90 0.88 0.354
IgG1-P181 15.48 0.0003
The F ratio, (i.e.. the ratio of the mean square for the effect divided by the mean square of the error) was calculated, and F statistics were used in
order to determine that the effect test was null. By testing the hypothesis that the lack of fit was zero, the F test indicated if all parameters of an
individual effect were null. The probabilities indicated in the Table correspond to the significance levels determined for the F ratio values (i.e. the
probability that given that the null hypothesis is true, an even larger F statistic would occur due to random error). Using Bonferroni correction (i.e.
taking into account that 18 different statistical tests were carried out), individual p values ≤0.0028 can still be considered as significant.
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